Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Dr Schär
Mandate

Vinge advised Dr Schär

February 29, 2024 M&A EU, Competition and Regulatory Carve-Outs

Vinge advised Dr Schär in the acquisition of Semper AB:s glutenfree business Dr. Schär, an Italian based company, is a developer of product for special nutritional needs.

Vinge advised Dr. Schär in its acquisition of Semper AB's gluten free business in the Nordics. Vinge's team was headed by Wibeke Sorling (Partner, M&A) and consisted mainly of a team managed by Anna Palmérus (Partner, EU & Competition law), Jenny Sandlund (Senior associate, M&A) and Victoria Gunnerek (Senior Associate, EU & Competition law).

Related

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

 Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026

Vinge advises Telavox on the sale of its Nordic customer base to Telia

 Vinge has advised Telavox AB (“Telavox”) on the sale of Telavox’s Nordic customer base for business services to Telia Company AB (“Telia”). The customer base comprises approximately 24,000 business customers and 325,000 end users in Sweden, Denmark, Finland, and Norway. The purchase price amounts to SEK 3.8 billion plus a potential additional earn-out.
November 13, 2026

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026